ZAI LAB LTD0000006(1ZLB)

Description: Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.

---

Keywords: Cancer Infectious Diseases Tumor Neuroscience Colorectal Cancer Pancreatic Cancer Nsclc Treating Cancer Cancer Therapy Autoimmune Disorders Portable Device Skin And Skin Structure Infections Gastrointestinal Stromal Tumors Bacterial Pneumonia Antibody–Drug Conjugate Omadacycline Serious Infections Gastric And Gastroesophageal Junction Cancer Pretreated Cancer Sulbactam Tisotumab Vedotin Acinetobacter Beta Lactamase Inhibitors Durlobactam Monomethyl Auristatin E Niraparib Sulbactam/Durlobactam Tesaro β Lactamase Inhibitor

---

Home Page: www.zailaboratory.com

Jinchuang Plaza
Shanghai, 201210
China
Phone: 86 21 6163 2588

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)